



October 15, 2020  
Q4 Newsletter

Welcome to the ARLG Newsletter! Here, you will receive important updates from ARLG regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will impact the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria.

### Get Involved with ARLG

ARLG continuously accepts proposals for clinical studies designed to prevent, diagnose, treat, or eradicate antibiotic-resistant bacterial pathogens. We also award grants and fellowships to qualified investigators. If you are interested in getting involved with ARLG, apply now or contact us for more information.

[Submit a Proposal](#)

[Contact Us](#)

## ARLG at IDWeek 2020

IDWeek starts Wed., Oct. 21! Tune in to hear ARLG thought leaders present a variety of interesting topics. To get you started, we've highlighted some key sessions you won't want to miss.

### Thurs., Oct. 22

11:00 a.m. - 12:15 p.m.  
**Interactive Session - Diagnostic  
Clinical Cases**

Speakers: Robin Patel (panelist)  
Christopher Doern (panelist)

### Fri., Oct. 23

10:00 a.m. - 11:15 a.m.  
**Challenging Cases in Infectious  
Diseases**

Moderator: Henry Chambers

Moderator: Kim Hanson

**12:30 p.m. - 1:45 p.m.**  
**Symposium - Epidemiologically Important Multi-drug Resistant Organisms in Transplantation**

Moderator: David van Duin

**3:45 p.m. - 5:00 p.m.**  
**Symposium - Clinical Trials That May Change Your Practice**

Speaker: Michael Satlin  
Moderators: Tom Holland  
Sarah Doernberg

**5:15 p.m. - 6:30 p.m.**  
**Bad Bugs - Any Drugs**

**Speakers:** David Paterson  
(panelist)  
Pranita Tamma  
(panelist)

**Moderators:** Robert Bonomo  
Sara Cosgrove

**4:15 p.m. - 5:30 p.m.**  
**Update on Novel Approaches to Antimicrobial Susceptibility Testing**

Speakers: Patricia Simner  
Lars Westblade

Moderator: Ritu Banerjee

**5:30 p.m. - 6:45 p.m.**  
**Maxwell Finland Lecture Featured Speaker**

*Staphylococcus aureus*: Lessons Learned from 20 Years with the Persistent Pathogen

Speaker: Vance G. Fowler

---

## On Demand

**Pediatric Infections and Immunology**

**Oral Abstract**

**Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)**

Speaker: W. Charles Huskins

---

See our website for the full list of ARLG speakers and topics!


[View All Sessions](#)

## Vance Fowler Tapped to be IDWeek 2020 Maxwell Finland Award Lecturer

ARLG co-principal investigator, Vance Fowler has been selected to present the Maxwell Finland Lecture at IDWeek 2020. The topic of the lecture will be “*Staphylococcus aureus*: Lessons Learned from 20 Years with the Persistent Pathogen.”


As an expert on *Staphylococcus aureus*, Dr. Fowler will discuss the impact that a single project can have on improved patient outcomes and summarize the importance of clinical, bacterial, and host genetic factors in influencing the initiation and severity of infections caused by *S. aureus*. The lecture will take place on October 23 at 5:30 p.m.

[Learn More](#)



Vance G. Fowler, Jr., MD, MHS

## ARLG SPOTLIGHT



**Jessica Howard-Anderson, MD, MSc**  
**Infectious Diseases Fellow**  
**Division of Infectious Diseases**  
**Emory University School of Medicine**

### About my role in the ARLG

I was awarded an ARLG fellowship beginning in January 2020 which provides full salary support for my research as well as funding for tuition and relevant training activities for 18 months.

### About my research

My primary ARLG research project focuses on patients with carbapenem-resistant *Pseudomonas aeruginosa* (CRPA). Using population-based surveillance data from the

Georgia Emerging Infections Program, I am analyzing clinical outcomes comparing patients initially treated with ceftolozane/tazobactam to those initially treated with colistin via a desirability of outcome ranking DOOR analysis.

### **Impact of the ARLG funding to my career**

The ARLG fellowship has been enormously beneficial to my career. By funding my fellowship salary, I have completely protected research time where I can focus on gaining the skills and generating additional data that I will need to apply for future career development awards.

The ARLG has also provided me with numerous opportunities to gain mentorship from and collaborate with ARLG investigators including those in the Gram-negative Committee and DOOR Exploratory Endpoint Task Force. They have supported my work and helped me advance my career as an independent researcher in antibacterial resistance.

[Read More](#)

## **News**

### **Deadline Alert for 2021 ARLG Fellowship Applications!**

Don't miss your chance! The last day to apply for a 2021 ARLG fellowship is December 1, 2020. Infectious diseases fellows who are interested in pursuing training, research, and a future career in antibacterial resistance clinical research are encouraged to pursue this competitive opportunity.

The fellowship is a two-year, fully funded program. Participants selected to take part will be offered mentoring from senior ARLG members. They will have the opportunity to receive formal training in epidemiology or statistics at the [Duke University School of Medicine Clinical Research Training Program](#) or an equivalent program at another institution in addition to a clinical research core-training curriculum.

Recipients will also be offered opportunities for integration into the ARLG mission and programs. Funding will be available in July 2021.

To learn more or to submit your application, go to the [ARLG Fellowships page](#).

**The submission deadline is December 1, 2020.**

[Apply Today](#)

## Take the Wellcome Global Health Survey



Healthcare workers who prescribe antimicrobial agents - the Drug Resistant Infections team at Wellcome needs your help!

In an effort to better understand clinical and public health gaps, Wellcome has launched a global survey aimed at collecting data on current prescribing practices in high, low, and middle-income countries. The information collected will help to prioritize funding to areas of critical need. The survey will close on October 20, 2020.

You can help by taking the survey [here](#).

---

## TMC AMR Registration and Abstract Deadline

Don't forget to register! The Texas Medical Center has partnered with ARLG to bring you the 4<sup>th</sup> Annual Texas Medical Center Antimicrobial Resistance and Stewardship Virtual conference happening January 26 – 28, 2021.

The deadline for abstracts is approaching quickly. Be sure to submit your abstract no later than December 18, 2020.

[Event Registration](#)

[Submit Your Abstract](#)



## Recent Publications

View the following recent ARLG publications.

Anesi JA, Blumberg EA, Han JH, Lee DH, Clauss H, Climaco A, Hasz R, Molnar E, Alimenti D, West S, Bilker WB, Tolomeo P, Lautenbach E. Risk factors for multidrug-resistant organisms among deceased organ donors. *Am J Transplant*. 2019 Sep;19(9):2468-2478. doi: 10.1111/ajt.15488. Epub 2019 Jun 26.

O'Donnell JN, Xu A, Lodise TP. Intravenous Compatibility of Ceftazidime-Avibactam plus Aztreonam using Simulated and Actual Y-site Administration. *Clin Ther*. 2020 Aug;42(8):1580-1586.e2. doi: 10.1016/j.clinthera.2020.06.005. Epub 2020 Jul 16.

Lodise TP, Smith NM, O'Donnell N, Eakin AE, Holden PN, Boissonneault KR, Zhou J, Tao X, Bulitta JB, Fowler Jr VG, Chambers HF, Bonomo RA, Tsuji BT. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. *J Antimicrob Chemother.* 2020 Sep 1;75(9):2622-2632. doi: 10.1093/jac/dkaa197.

Tanaka JS, Young RR, Heston SM, Jenkins K, Spees LP, Sung AD, Corbet K, Thompson J, Bohannon L, Martin PL, Vinesett R, Ward DV, Bhattarai SK, Buccì V, Seed PC, Kelly MS. Anaerobic Antibiotics and the Risk of Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2020;S1083-8791(20)30442-0. doi: 10.1016/j.bbmt.2020.07.011. Online ahead of print.

Howard-Anderson J, Webster A, Goyal A, Vadnais DS, Kraft CS, Steinberg JP, Jacob JT. COVID-19 or Common Coronavirus? A Cautionary Tale in Advanced Diagnostics. *Diagnosis (Berl).* 2020 Jul 25;/j/dx.ahead-of-print/dx-2020-0093/dx-2020-0093.xml. doi: 10.1515/dx-2020-0093. Online ahead of print.

Duke Clinical Research Institute | 300 West Morgan Street, Suite 800, Durham, NC 27701

[Unsubscribe {recipient's email}](#)

[Update Profile](#) | [About our service provider](#)

Sent by arlg-newsletter@dm.duke.edu powered by



Try email marketing for free today!